摘要
目的探讨北京儿童医院-2003方案(BCH-2003)和中国儿童白血病协作组-2008(CCLG-2008)方案对急性淋巴细胞白血病(ALL)患儿临床疗效及预后的影响。方法依据化疗方案的不同将98例ALL患儿分为BCH-2003组(n=49)和CCLG-2008组(n=49),BCH-2003组患儿给予BCH-2003方案化疗,CCLG-2008组患儿给予CCLG-2008方案化疗。比较两组患儿的临床疗效、血清相关指标[血管内皮生长因子(VEGF)、血管内皮生长因子受体(VEGFR)、碱性成纤维细胞生长因子(bFGF)]、不良反应发生情况及随访5年复发情况。结果治疗后,BCH-2003组患儿的治疗总有效率为89.80%,高于CCLG-2008组患儿的73.47%,差异有统计学意(P﹤0.05)。治疗后,两组患儿VEGF、VEFGR、bFGF水平均低于本组治疗前,且CCLG-2008组患儿VEGF、VEFGR、bFGF水平均低于BCH-2003组,差异均有统计学意义(P﹤0.05)。CCLG-2008组患儿神经系统症状、消化系统症状发生率均低于BCH-2003组,差异均有统计学意义(P﹤0.05)。随访5年,CCLG-2008组患儿的复发率为8.16%,明显低于BCH-2003组患儿的40.82%,差异有统计学意义(P﹤0.01)。结论相较于CCLG-2008方案,BCH-2003方案治疗ALL患儿的近期疗效更好,但CCLG-2008方案的不良反应发生率及复发率更低。
Objective To investigate the effects of Beijing Children’s Hospital(BCH)-2003 and Chinese Children’s Leukemia Group(CCLG)-2008 program on the clinical efficacy and prognosis of children with acute lymphoblastic leukemia(ALL).Method According to different chemotherapy regimens,98 children with ALL were divided into BCH-2003 group(n=49)and CCLG-2008 group(n=49).Children in BCH-2003 group were given BCH-2003 chemotherapy,and children in CCLG-2008 group were given CCLG-2008 chemotherapy.The clinical efficacy,serum-related indexes[vascular endothelial growth factor(VEGF),vascular endothelial growth factor receptor(VEGFR),basic fibroblast growth factor(bFGF)],adverse reactions and recurrence after 5-year follow-up were compared between the two groups.Result After treatment,the total effective rate of BCH-2003 group was 89.80%,which was higher than 73.47% of CCLG-2008 group,the difference was statistically significant(P<0.05).After treatment,the levels of VEGF,VEFGR and bFGF in the two groups were lower than those before treatment,and the levels of VEGF,VEFGR and bFGF in CCLG-2008 group were lower than those in BCH-2003 group,the differences were statistically significant(P<0.05).The incidences of neurological symptoms and digestive system symptoms in the CCLG-2008 group were lower than those in the BCH-2003 group,and the differences were statistically significant(P<0.05).After 5 years of follow-up,the recurrence rate of CCLG-2008 group was 8.16%,which was significantly lower than 40.82%in BCH-2003 group,the difference was statistically significant(P<0.01).Conclusion Compared with the CCLG-2008 regimen,the BCH-2003 regimen has better short-term efficacy in the treatment of children with ALL,but the CCLG-2008 regimen has a lower incidence of adverse reactions and recurrence rates.
作者
赵静
尹清澄
孙培卓
姚金晓
ZHAO Jing;YIN Qingdeng;SUN Peizhuo;YAO Jinxiao(Department of Pediatrics,Nanyang Second General Hospital,Nanyang 473000,He’nan,China)
出处
《癌症进展》
2022年第13期1374-1376,1380,1384,共5页
Oncology Progress
